Central and Peripheral Fatigue: Exemplified by Multiple Sclerosis and Myasthenia Gravis

PM and R

Volumn 2, Issue 5, 2010, Pages 399-405

  Cantor, Fredric ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA INTERFERON; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CORTICOSTEROID; EDROPHONIUM; GAMMA INTERFERON; MODAFINIL; NATALIZUMAB; PEMOLINE; PSYCHOSTIMULANT AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ARTICLE; BEDTIME DOSAGE; BRAIN FUNCTION; COGNITION; DAYTIME SOMNOLENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG SAFETY; ELECTROMYOGRAPHY; ENVIRONMENTAL TEMPERATURE; EXERCISE; FATIGUE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMMUNOMODULATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELINATION; NERVE CONDUCTION; NEUROMUSCULAR SYNAPSE; OCCUPATIONAL THERAPY; OXYGEN CONSUMPTION; PARESTHESIA; PATHOGENESIS; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

COMORBIDITY; DISEASE PROGRESSION; FATIGUE; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL FATIGUE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; SLEEP DISORDERS;

EID: 77952818833     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2010.04.012     Document Type: Article

References (64)

1. Schwid S.R., Thornton C.A., Pandya S., et al. Quantitative assessment of motor fatigue and strength in MS. Neurology 53 (1999) 743-750
2. Schwid S.R., Tyler C.M., Scheid E.A., Weinstein A., Goodman A.D., and McDermott M.P. Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler 9 (2003) 503-508
3. Bergamaschi R., Romani A., Versino M., Poli R., and Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 12 (1997) 247-251
4. Kurtzke J.F. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology 31 (2008) 1-9
5. Pellicano C Gallo A, Li X, et al. Cortical atrophy is related to fatigue in patients with multiple sclerosis. Arch Neurol. In press.
6. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 9 (2003) 219-227
7. Rosenberg JH S.R. Fatigue in multiple sclerosis: A rational approach to evaluation and treatment. Curr Neurol Neurosci Rep 5 (2005) 140-146
8. Humm A.M., Beer S., Kool J., Magistris M.R., Kesselring J., and Rosler K.M. Quantification of Uhthoff's phenomenon in multiple sclerosis: A magnetic stimulation study. Clin Neurophysiol 115 (2004) 2493-2501
9. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis (1998), Paralyzed Veterans of America, Washington, DC
10. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., and Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 72 (2002) 179-183
11. El-Moslimany H., and Lublin F.D. Clinical features in multiple sclerosis. In: Raine C.S., McFarland H.F., and Hohlfeld R. (Eds) (2008), Saunders/Elsevier, Edinburgh
12. Greim B., Benecke R., and Zettl U.K. Qualitative and quantitative assessment of fatigue in multiple sclerosis (MS). J Neurol 254 Suppl 2 (2007) II58-II64
13. Koch M., Mostert J., Heerings M., Uyttenboogaart M., and De Keyser J. Fatigue, depression and disability accumulation in multiple sclerosis: A cross-sectional study. Eur J Neurol 16 (2009) 348-352
14. Logsdon R.G., and Teri L. Depression in Alzheimer's disease patients: Caregivers as surrogate reporters. J Am Geriatr Soc 43 (1995) 150-155
15. Brass S.D., Duquette P., Proulx-Therrien J., and Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev 14 (2009) 121-129
16. Fleming W.E., and Pollak C.P. Sleep disorders in multiple sclerosis. Semin Neurol 25 (2005) 64-68
17. Johns M.W. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14 (1991) 540-545
18. Strober L.B., and Arnett P.A. An examination of four models predicting fatigue in multiple sclerosis. Arch Clin Neuropsychol 20 (2005) 631-646
19. Colombo N., Boneschi F., Rossi P., et al. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol 247 (2000) 506-509
20. Bakshi R.M.R., Kinkel P.R., Emmet M.L., and Kinkel W.R. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 8 (1998) 228-234
21. Roelke U., Kappos L., and Lechner-Scott J. Reduced glucose metabolism in frontal cortex of basal ganglia of multiple sclerosis patients with fatigue. Neurology 48 (1997) 1566-1571
22. Filippi M., Rocca M.A., Colombo B., et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 15 (2002) 559-567
23. Marrie R.A., Fisher E., Miller D., Lee J.-C., and Rudick R. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 228 (2005) 161-166
24. Tartaglia M.C., Narayanan S., and Arnold D.L. Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue. Eur J Neurol 15 (2008) 413-419
25. Geurts J.J., and Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol 7 (2008) 841-851
26. Smith K.J. Conduction properties of central demyelinated and remyelinated axons and their relation to symptom production in demyelinating disorders. Eye 8 (1994) 224-237
27. Kocis J., and Waxman S.G. Neurophysiology of demyelination. In: Raine C., McFarland H.F., and Hohlfeld R. (Eds). Multiple Sclerosis (2008), Saunders, New York 178-191
28. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 28 (1973) 287-292
29. Hautecoeur P., Forzy G., Gallois P., Demirbilek V., and Feugas O. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg 97 (1997) 240-243
30. Heesen C., Nawrath L., Reich C., Bauer N., Schulz K.H., and Gold S.M. Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour?. J Neurol Neurosurg Psychiatry 77 (2006) 34-39
31. Flachenecker P., Bihler I., Weber F., Gottschalk M., Toyka K.V., and Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler 10 (2004) 165-169
32. Khademi M., Stol D., Olsson T., and Wallstrom E. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol 15 (2008) 309-312
33. Gayo A., Mozo L., Suarez A., Tunon A., Lahoz C., and Gutierrez C. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS. Neurology 52 (1999) 1764-1770
34. Greim B., Engel C., Apel A., and Zettl U.K. Fatigue in neuroimmunological diseases. J Neurol 254 Suppl 2 (2007) II102-II106
35. Davis M.C., Zautra A.J., Younger J., Motivala S.J., Attrep J., and Irwin M.R. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun 22 (2008) 24-32
36. Anisman H., and Merali Z. Cytokines, stress and depressive illness: Brain-immune interactions. Ann Med 35 (2003) 2-11
37. Giovannoni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry 77 (2006) 2-3
38. Gottschalk M., Kumpfel T., Flachenecker P., et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 62 (2005) 277-280
39. Lebrun C., Alchaar H., Candito M., Bourg V., and Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 12 (2006) 321-324
40. Tomassini V., Pozzilli C., Onesti E., et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218 (2004) 103-108
41. Neill J., Belan I., and Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs 56 (2006) 617-635
42. Mostert S., and Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 8 (2002) 161-168
43. Di Fabio R.P., Soderberg J., Choi T., Hansen C.R., and Schapiro R.T. Extended outpatient rehabilitation: Its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil 79 (1998) 141-146
44. Rietberg M.B., Brooks D., Uitdehaag B.M., and Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev (2005) CD003980
45. Grahn D.A., Murray J.V., and Heller H.C. Cooling via one hand improves physical performance in heat-sensitive individuals with multiple sclerosis: A preliminary study. BMC Neurol 8 (2008) 14
46. Nilsagard Y., Denison E., and Gunnarsson L.G. Evaluation of a single session with cooling garment for persons with multiple sclerosis-a randomized trial. Disabil Rehabil Assist Technol 1 (2006) 225-233
47. Branas P., Jordan R., Fry-Smith A., Burls A., and Hyde C. Treatments for fatigue in multiple sclerosis: A rapid and systematic review. Health Technol Assess 4 (2000) 1-61
48. Lee D., Newell R., Ziegler L., and Topping A. Treatment of fatigue in multiple sclerosis: A systematic review of the literature. Int J Nurs Pract 14 (2008) 81-93
49. Judge S.I., and Bever Jr. C.T. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111 (2006) 224-259
50. Van Lunteren E., Moyer M., and Pollarine J. Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation. Muscle Nerve 38 (2008) 1616-1622
51. Stankoff B., Waubant E., Confavreux C., et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology 64 (2005) 1139-1143
52. Littleton E.T., Hobart J.C., and Palace J. Modafinil for multiple sclerosis fatigue: Does it work?. Clin Neurol Neurosurg 112 (2009) 29-31
53. Schwid S.R., and Murray T.J. Treating fatigue in patients with MS: One step forward, one step back. Neurology 64 (2005) 1111-1112
54. Schwid S.R., Covington M., Segal B.M., and Goodman A.D. Fatigue in multiple sclerosis: Current understanding and future directions. J Rehabil Res Dev 39 (2002) 211-224
55. Ciccone A., Beretta S., Brusaferri F., Galea I., Protti A., and Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev (2008) CD006264
56. Humm A.M., Z'Graggen W.J., Buhler R., Magistris M.R., and Rosler K.M. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry 77 (2006) 345-350
57. Symonette C.J., Watson B.V., Koopman W.J., Nicolle M.W., and Doherty T.J. Muscle strength and fatigue in patients with generalized myasthenia gravis. Muscle Nerve 41 (2009) 362-369
58. Kinali M., Beeson D., Pitt M.C., et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol (2008) 201-202 6-12
59. Engel A.G. Neuromuscular manifestations of Graves' disease. Mayo Clin Proc 47 (1972) 919-925
60. Lucchi M., Ricciardi R., Melfi F., et al. Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment. Eur J Cardiothorac Surg 35 (2009) 812-816 discussion 816
61. Gilhus N.E. Autoimmune myasthenia gravis. Expert Rev Neurother 9 (2009) 351-358
62. Sanders D.B. The electrodiagnosis of myasthenia gravis. Ann N Y Acad Sci 505 (1987) 539-556
63. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
64. Matsui M., Wada H., Ohta M., and Kuroda Y. Potential role of thymoma and other mediastinal tumors in the pathogenesis of myasthenia gravis. J Neuroimmunol 44 (1993) 171-176